Related Experiment Videos
Thrombolytic therapy in acute myocardial infarction
Insights
Thrombolytic therapy effectively treats acute myocardial infarction, reducing deaths and preserving heart function. Despite its benefits, this life-saving treatment remains underutilized globally.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Thrombolytic therapy significantly reduces mortality and preserves left ventricular function in acute myocardial infarction.
- Despite proven benefits, thrombolytic therapy is underused in many countries.
- Current indications for thrombolysis can be expanded to include specific patient groups and prehospital settings.
Purpose of the Study:
- To review the current status and potential improvements in thrombolytic therapy for acute myocardial infarction.
- To highlight strategies for increasing the utilization and effectiveness of thrombolytic treatment.
- To emphasize the importance of rapid reperfusion for patient survival and quality of life.
Main Methods:
- Review of existing literature and clinical trial data on thrombolytic therapy for acute myocardial infarction.
- Analysis of factors contributing to underutilization and strategies for improvement.
- Discussion of adjunctive therapies and optimal reperfusion goals.
Main Results:
- Thrombolytic therapy is safe, cost-effective, and improves outcomes in acute myocardial infarction.
- Prehospital thrombolysis is feasible and cost-effective in certain settings.
- Achieving Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow is critical for ventricular function and survival.
- Optimal reperfusion is achieved in only about half of patients with current regimens.
Conclusions:
- Thrombolytic therapy is a cornerstone of acute myocardial infarction treatment but requires wider application.
- Shortening "door to needle" time and expanding indications are crucial for improving patient outcomes.
- Further advancements in thrombolytic, antiplatelet, and antithrombotic therapies are needed to enhance early and complete reperfusion, thereby improving survival and quality of life.
Abstract:
Thrombolytic therapy has revolutionized the treatment of acute myocardial infarction by reducing mortality and preserving left ventricular function. It is relatively safe and cost-effective. However, it is currently underused in most countries. Patients in whom thrombolysis is indicated include those with ST elevation on the electrocardiogram or bundle branch block pattern who present within 12 hours of myocardial infarction; the indications should be widened to include the elderly, patients who have undergone nontraumatic cardiopulmonary resuscitation, and women during menstruation. The risk-benefit ratio should be assessed for the individual patient. Prehospital thrombolytic treatment has been shown to be feasible with the support of well-trained staff and resuscitation equipment, and may be cost-effective in communities with time delays before hospitalization greater than 1 hour. The most important strategy is to shorten the "door to needle" time in hospital. The importance of full infarct-related artery flow (Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow) for preservation of ventricular function and survival has been documented in the second Thrombolysis Trial of Eminase in Acute Myocardial Infarction (TEAM 2) and the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) studies. Aspirin and heparin are beneficial adjunctive regimens to thrombolytic therapy but optimal epicardial reperfusion is achieved in only about half of patients. Improved thrombolytic, adjunctive antiplatelet, and antithrombotic regimens are required to achieve early full reperfusion, which is crucial to improve survival and quality of life.